-
The INVITAE Cancer Risk test receives FDA marketing approval
The INVITAE Cancer Risk test receives FDA marketing approval. -
AstraZeneca acquires a Chinese cancer drug developer with a transaction value of approximately $1.2 billion
AstraZeneca announced on Tuesday local time that a final agreement has been signed on the proposed acquisition of Gracell, which will add GC012F CAR-T cell therapy to AstraZeneca's expanding cell the ... -
Merck is in deep negotiations to acquire cancer drug manufacturer HARPOON Therapeutics for approximately $700 million
Merck is in deep negotiations to acquire cancer drug manufacturer HARPOON Therapeutics for approximately $700 million. -
Merck's small molecule cancer drug, acquired for over $1.3 billion, launches Phase 3 clinical trials in China
According to the latest announcement on the Chinese Drug Clinical Trial Registration and Information Disclosure Platform, Merck's Class 1 oral drug MK-3543 (bomedemstat) for the treatment of primary ... -
Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China. On September 2nd, Bristol Myers Squibb China announced that the original tumor treatment drug Abra ...